Identification of RAS-mitogen-activated protein kinase signaling pathway modulators in an ERF1 redistribution screen

• Published in: Journal of biomolecular screening Vol. 11; no. 4; pp. 423 - 434
• Main Authors: Grånäs, Charlotta, Lundholt, Betina Kerstin, Loechel, Frosty, Pedersen, Hans-Christian, Bjørn, Sara Petersen, Linde, Viggo, Krogh-Jensen, Christian, Nielsen, Eva-Maria Damsgaard, Praestegaard, Morten, Nielsen, Søren Jensby
• Format: Journal Article
• Language: English
• Published: United States 01.06.2006
• Subjects: Animals; Cell Line; Cell Line, Tumor; Cell Proliferation - drug effects; Cricetinae; DNA-Binding Proteins - antagonists & inhibitors; DNA-Binding Proteins - genetics; Drug Evaluation, Preclinical - methods; Humans; In Vitro Techniques; MAP Kinase Signaling System - drug effects; MAP Kinase Signaling System - genetics; Molecular Structure; Phosphorylation; Repressor Proteins - antagonists & inhibitors; Repressor Proteins - genetics; RNA, Small Interfering - genetics; Transcription Factors - antagonists & inhibitors; Transcription Factors - genetics; Transfection
• ISSN: 1087-0571; 2472-5552; 1552-454X
• DOI: 10.1177/1087057106287136

The RAS-mitogen-activated protein kinase (MAPK) signaling pathway has a central role in regulating the proliferation and survival of both normal and tumor cells. This pathway has been 1 focus area for the development of anticancer drugs, resulting in several compounds, primarily kinase inhibitors, in clinical testing. The authors have undertaken a cell-based, high-throughput screen using a novel ERF1 Redistribution assay to identify compounds that modulate the signaling pathway. The hit compounds were subsequently tested for activity in a functional cell proliferation assay designed to selectively detect compounds inhibiting the proliferation of MAPK pathway-dependent cancer cells. The authors report the identification of 2 cell membrane-permeable compounds that exhibit activity in the ERF1 Redistribution assay and selectively inhibit proliferation of MAPK pathway-dependent malignant melanoma cells at similar potencies (IC(50)=< 5 microM). These compounds have drug-like structures and are negative in RAF, MEK, and ERK in vitro kinase assays. Drugs belonging to these compound classes may prove useful for treating cancers caused by excessive MAPK pathway signaling. The results also show that cell-based, high-content Redistribution screens can detect compounds with different modes of action and reveal novel targets in a pathway known to be disease relevant.